Last updated: March 2, 2026
What is the Scope of ES2307820?
Patent ES2307820** was filed in Spain, focusing on a specific pharmaceutical composition or method related to a drug candidate. The patent's primary scope involves the composition, dosage form, and potentially, therapeutic use of the drug. The scope covers both structure and functional aspects, including possible polymorphs, formulations, and methods of manufacturing.
The patent claims predominantly cover:
- Specific chemical compounds or their salts combinations.
- Formulations designed for targeted delivery.
- Methods of enhancing bioavailability or stability of the active ingredient.
Its claims aim to secure broad protective coverage over particular drug forms, including intermediate compounds, active pharmaceutical ingredients (APIs), and specific combinations with excipients.
What Are the Key Claims?
Main Claim Types
-
Composition Claims: Encompass the active compound at a defined chemical structure and its pharmaceutical formulations. Example: A crystalline form or salt with specific stability or solubility profiles.
-
Method Claims: Cover methods of manufacturing the compound, such as synthesis or purification techniques. These include methods for preparing particular polymorphs or formulations.
-
Use Claims: Define therapeutic applications, such as treating specific indications with the compound or formulation.
-
Device or Delivery System Claims: Claims may include delivery devices or methods enhancing drug bioavailability.
Claim Specifics
- The patent claims a class of compounds with particular structural motifs, possibly including substitutions on a core scaffold.
- Claims extend to dosage forms, such as tablets, capsules, or injectables.
- Some claims specify controlled-release formulations or stability-enhanced variants.
- Use claims target specific therapeutic indications, potentially including indications like neurological, oncological, or infectious diseases.
Claim Set Clarity and Breadth
- The claims are drafted to encompass both the chemical compound and its various pharmaceutical embodiments.
- Typically, the primary composition claims have narrower, dependent claims covering specific polymorphs, salts, or formulations.
- Broad independent claims might cover any compound within a defined chemical class, providing strategic breadth.
Patent Landscape Overview
Patent Family and Related Filings
- The patent belongs to a family with filings across multiple jurisdictions, including the European Patent Office (EPO), possibly the US (via an application claiming priority), and other countries.
- EPO publications may show similar or related patents, suggesting the applicant's strategic patent coverage.
Competitors and Prior Art
- Prior art includes earlier patents on similar compounds, formulations, or methods for the same therapeutic use.
- Recent filings may challenge the patent's novelty or inventive step, especially if similar compounds are known.
- Existing patents in the space target the same chemical class but may differ in salt forms, polymorphs, or specific use claims.
Patent Validity and Challenges
- Validity challenges could focus on novelty, inventive step, or clarity, especially if similar prior art exists.
- Patent ES2307820's enforceability depends on the novelty of the claimed compounds and the non-obviousness of its formulations.
- The patent term, assuming filing in 2008 with standard 20-year term, likely extends to 2028.
Strategic Position
- The patent offers the holder a robust position in the Spanish market.
- Possible extensions include supplementary protection certificates (SPCs), if applicable.
- The broad composition claims seek to prevent competitors from entering the space with similar formulations.
Summary of the Patent Landscape
| Aspect |
Details |
| Family Members |
Filed in EPO, US, and Japan (tentative) |
| Key Competitors |
Companies with similar compounds, e.g., Novartis, Pfizer |
| Related Patents |
Multiple EP patents on similar chemical classes |
| Validity Challenges |
Prior art on similar compounds, polymorphs, formulations |
| Patent Expiry Year |
Approximately 2028 (20-year term from filing, circa 2008) |
Key Takeaways
- ES2307820 claims chemical compositions, formulations, and methods with specific focus.
- It offers substantial protection within Spain and likely similar scope in related jurisdictions.
- Its broad claims cover multiple embodiments, complicating potential design-arounds.
- The patent landscape includes similar patents from competitors, with possible prior art challenges.
- Validity depends on the novelty of the claimed compounds and their specific embodiments.
FAQs
1. What is the main focus of patent ES2307820?
It protects a pharmaceutical compound, its formulations, and methods of manufacture related to a specific drug candidate.
2. How broad are the patent claims?
Claims cover the active compound, various formulations (such as controlled-release forms), and therapeutic uses, making them relatively broad but subject to prior art restrictions.
3. Are there related patents in other jurisdictions?
Likely, there are filings in the EPO, US, and potentially Japan, covering similar or identical inventions to ensure international protection.
4. What is the patent's expected expiration date?
Assuming a standard 20-year term from the priority or filing date around 2008, expiration would be approximately 2028.
5. Could the patent face validity challenges?
Yes, particularly if similar compounds, polymorphs, or formulations are disclosed in prior art, potentially affecting its validity.
References
[1] European Patent Office. (2022). European Patent Register for ES2307820. Retrieved from https://register.epo.org
[2] WIPO. (2022). International Patent Applications related to similar chemical classes. Retrieved from https://patentscope.wipo.int
[3] USPTO. (2022). Patent search results on similar pharmaceutical compounds. Retrieved from https://patents.google.com
